Zacks: Brokerages Expect Pacira Pharmaceuticals Inc (PCRX) to Post $0.22 EPS

Wall Street analysts expect that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will announce earnings per share (EPS) of $0.22 for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Pacira Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.04 and the highest estimate coming in at $0.35. Pacira Pharmaceuticals posted earnings per share of $0.38 during the same quarter last year, which would indicate a negative year-over-year growth rate of 42.1%. The business is scheduled to report its next quarterly earnings report on Wednesday, February 27th.

On average, analysts expect that Pacira Pharmaceuticals will report full-year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.60 to $0.92. For the next financial year, analysts forecast that the company will post earnings of $1.25 per share, with EPS estimates ranging from ($0.44) to $1.87. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.40. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The business had revenue of $83.45 million during the quarter, compared to the consensus estimate of $79.87 million. During the same period in the previous year, the company posted $0.11 earnings per share. The business’s revenue for the quarter was up 23.9% on a year-over-year basis.

A number of equities analysts have recently commented on PCRX shares. Barclays boosted their price objective on Pacira Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, August 6th. ValuEngine raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. Needham & Company LLC raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Friday, August 3rd. HC Wainwright reissued a “buy” rating and set a $52.00 price objective on shares of Pacira Pharmaceuticals in a research report on Friday, August 3rd. They noted that the move was a valuation call. Finally, Piper Jaffray Companies set a $48.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $52.28.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The stock was purchased at an average price of $44.61 per share, for a total transaction of $44,610.00. Following the completion of the purchase, the director now directly owns 8,577 shares in the company, valued at $382,619.97. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Andreas Wicki sold 5,478 shares of the business’s stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $49.83, for a total value of $272,968.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,390 shares of company stock valued at $3,429,069. 5.90% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Granahan Investment Management Inc. MA lifted its stake in Pacira Pharmaceuticals by 12.3% during the second quarter. Granahan Investment Management Inc. MA now owns 188,086 shares of the company’s stock worth $6,028,000 after purchasing an additional 20,617 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in Pacira Pharmaceuticals by 15.3% in the second quarter. Mutual of America Capital Management LLC now owns 155,554 shares of the company’s stock valued at $4,986,000 after buying an additional 20,606 shares during the last quarter. Mizuho Securities USA LLC lifted its stake in Pacira Pharmaceuticals by 193.8% in the third quarter. Mizuho Securities USA LLC now owns 23,500 shares of the company’s stock valued at $1,155,000 after buying an additional 15,500 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Pacira Pharmaceuticals by 14.7% in the second quarter. Russell Investments Group Ltd. now owns 56,610 shares of the company’s stock valued at $1,813,000 after buying an additional 7,249 shares during the last quarter. Finally, United Services Automobile Association lifted its stake in Pacira Pharmaceuticals by 10.9% in the second quarter. United Services Automobile Association now owns 127,822 shares of the company’s stock valued at $4,097,000 after buying an additional 12,600 shares during the last quarter.

Shares of Pacira Pharmaceuticals stock traded down $0.27 on Thursday, reaching $47.27. 639,000 shares of the company were exchanged, compared to its average volume of 804,327. Pacira Pharmaceuticals has a 1-year low of $26.95 and a 1-year high of $55.00. The company has a market cap of $1.99 billion, a PE ratio of -81.50 and a beta of 1.68. The company has a debt-to-equity ratio of 0.95, a quick ratio of 7.83 and a current ratio of 8.66.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Recommended Story: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply